These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31173518)

  • 41. Peptide-based supramolecular vaccine systems.
    O'Neill CL; Shrimali PC; Clapacs ZE; Files MA; Rudra JS
    Acta Biomater; 2021 Oct; 133():153-167. PubMed ID: 34010691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DNA vaccines: an historical perspective and view to the future.
    Liu MA
    Immunol Rev; 2011 Jan; 239(1):62-84. PubMed ID: 21198665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biomaterials for vaccine-based cancer immunotherapy.
    Zhang R; Billingsley MM; Mitchell MJ
    J Control Release; 2018 Dec; 292():256-276. PubMed ID: 30312721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peptide vaccines against cancer, infectious diseases, and conception.
    Naz RK; Dabir P
    Front Biosci; 2007 Jan; 12():1833-44. PubMed ID: 17127424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery.
    Falcone N; Ermis M; Tamay DG; Mecwan M; Monirizad M; Mathes TG; Jucaud V; Choroomi A; de Barros NR; Zhu Y; Vrana NE; Kraatz HB; Kim HJ; Khademhosseini A
    Adv Healthc Mater; 2023 Oct; 12(27):e2301096. PubMed ID: 37256647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current status and future prospects of peptide-based cancer vaccines.
    Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
    Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insect cell technology is a versatile and robust vaccine manufacturing platform.
    Mena JA; Kamen AA
    Expert Rev Vaccines; 2011 Jul; 10(7):1063-81. PubMed ID: 21806400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antitumor vaccination using peptide based vaccines.
    Eisenbach L; Bar-Haim E; El-Shami K
    Immunol Lett; 2000 Sep; 74(1):27-34. PubMed ID: 10996624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Personalized peptide vaccine for treatment of advanced cancer.
    Sasada T; Yamada A; Noguchi M; Itoh K
    Curr Med Chem; 2014; 21(21):2332-45. PubMed ID: 24524766
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peptide vaccines in breast cancer: The immunological basis for clinical response.
    Peres Lde P; da Luz FA; Pultz Bdos A; Brígido PC; de Araújo RA; Goulart LR; Silva MJ
    Biotechnol Adv; 2015 Dec; 33(8):1868-77. PubMed ID: 26523780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
    Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
    J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peptide-based vaccines for cancer therapy.
    Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
    Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent advances in peptide-based subunit nanovaccines.
    Skwarczynski M; Toth I
    Nanomedicine (Lond); 2014 Dec; 9(17):2657-69. PubMed ID: 25529569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surgery-free injectable macroscale biomaterials for local cancer immunotherapy.
    Lei K; Tang L
    Biomater Sci; 2019 Feb; 7(3):733-749. PubMed ID: 30637428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methods and Protocols for Developing Prion Vaccines.
    Marciniuk K; Taschuk R; Napper S
    Methods Mol Biol; 2016; 1403():657-80. PubMed ID: 27076159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Engineering vaccines and niches for immune modulation.
    Purwada A; Roy K; Singh A
    Acta Biomater; 2014 Apr; 10(4):1728-40. PubMed ID: 24373907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies.
    Hevey R; Ling CC
    Future Med Chem; 2012 Mar; 4(4):545-84. PubMed ID: 22416779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Noncanonical peptides in complex with MHC class I.
    Apostolopoulos V; Lazoura E
    Expert Rev Vaccines; 2004 Apr; 3(2):151-62. PubMed ID: 15056041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peptide-based materials for cancer immunotherapy.
    Zhang L; Huang Y; Lindstrom AR; Lin TY; Lam KS; Li Y
    Theranostics; 2019; 9(25):7807-7825. PubMed ID: 31695802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenically fit subunit vaccine components via epitope discovery from natural peptide libraries.
    Matthews LJ; Davis R; Smith GP
    J Immunol; 2002 Jul; 169(2):837-46. PubMed ID: 12097387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.